M G Murphy

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women
    M G Murphy
    Merck Research Laboratories, Rahway, New Jersey 07065 0900, USA
    J Clin Endocrinol Metab 86:1116-25. 2001
  2. ncbi Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women
    M G Murphy
    Merck Research Laboratories, Building 5W, Sentry Rahway, NJ 07065, USA
    J Clin Endocrinol Metab 90:2022-8. 2005
  3. ncbi Pharmacokinetic assessment of an oral enalapril suspension for use in children
    R K Rippley
    Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486 0004, USA
    Biopharm Drug Dispos 21:339-44. 2000
  4. ncbi Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers
    R Iannone
    Merck Research Laboratories, West Point, Pennsylvania, USA
    Clin Pharmacol Ther 88:831-9. 2010
  5. ncbi Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers
    S L de Haas
    Centre for Human Drug Research, Leiden, The Netherlands
    J Psychopharmacol 21:374-83. 2007
  6. ncbi Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers
    S L de Haas
    Centre for Human Drug Research, Leiden, The Netherlands
    J Psychopharmacol 22:24-32. 2008

Collaborators

Detail Information

Publications6

  1. ncbi Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women
    M G Murphy
    Merck Research Laboratories, Rahway, New Jersey 07065 0900, USA
    J Clin Endocrinol Metab 86:1116-25. 2001
    ....
  2. ncbi Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women
    M G Murphy
    Merck Research Laboratories, Building 5W, Sentry Rahway, NJ 07065, USA
    J Clin Endocrinol Metab 90:2022-8. 2005
    ..Furthermore, 200 mg L-000845704 bid provided efficacy at the hip sites. These data suggest that the alphaVbeta3 integrin antagonist L-000845704 could be developed as an effective therapeutic agent for osteoporosis...
  3. ncbi Pharmacokinetic assessment of an oral enalapril suspension for use in children
    R K Rippley
    Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486 0004, USA
    Biopharm Drug Dispos 21:339-44. 2000
    ..We conclude that the bioavailability of enalapril oral suspension 10-mg is similar to that of VASOTEC 10-mg tablet. Instructions for compounding enalapril are provided...
  4. ncbi Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers
    R Iannone
    Merck Research Laboratories, West Point, Pennsylvania, USA
    Clin Pharmacol Ther 88:831-9. 2010
    ..0001 for modafinil and for both doses of MK-0249). The alertness-promoting effect with the use of MK-0249 in the SRSDM suggests that HRH3 IAs may be effective in disorders involving excessive somnolence...
  5. ncbi Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers
    S L de Haas
    Centre for Human Drug Research, Leiden, The Netherlands
    J Psychopharmacol 21:374-83. 2007
    ..Contrary to lorazepam, TPA023 caused no detectable memory impairment or postural imbalance. These differences reflect the selectivity of TPA023 for different GABA(A) receptor subtypes...
  6. ncbi Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers
    S L de Haas
    Centre for Human Drug Research, Leiden, The Netherlands
    J Psychopharmacol 22:24-32. 2008
    ..Clinical studies in anxiety patients should show whether this dose of MK-0343 is therapeutically effective with a different side-effect profile...